Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy

A pilot study

Hee Song Lee, Junyoung Song, Kyunghoon Min, Yong Soo Choi, Sun Mi Kim, Sung-Rae Cho, Min Young Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objective: Cerebral palsy (CP) is a disabling condition characterized by the motor impairment, which is difficult to be ameliorated. In the brain of infants with CP, there are persistent pathomechanisms including accentuated neuroinflammation. Since erythropoietin was demonstrated to have neuroprotective effect via anti-inflammatory and anti-apoptotic properties, we hypothesized that the administration of recombinant human EPO (rhEPO) could help children with CP, especially young infants. Materials and method: We investigated the therapeutic efficacy of rhEPO for infants with CP, who had been undergoing active rehabilitation in hospitalized setting to eliminate treatment bias. Twenty infants with CP were randomly divided into EPO or control group equally. We compared the changes in the Gross Motor Function Measure (GMFM) and the Bayley Scales of Infant Development-II (BSID-II) scores during one month of hospitalization between two groups. Results: The improvements after 1month on the GMFM A and GMFM total scores differed significantly between the groups (p=0.003, p=0.04, respectively). However, the changes after 6months were not different between the two groups. The scores of BSID-II did not show any differences at 1-month and 6-months post-treatment. Conclusion: These results indicated that rhEPO could have therapeutic efficacy for infants with CP during the active rehabilitation and anti-inflammation was suggested to be one of its therapeutic mechanisms.

Original languageEnglish
Pages (from-to)764-769
Number of pages6
JournalBrain and Development
Volume36
Issue number9
DOIs
Publication statusPublished - 2014 Oct 1

Fingerprint

Cerebral Palsy
Erythropoietin
Child Development
Rehabilitation
Therapeutics
Neuroprotective Agents
Hospitalization
Anti-Inflammatory Agents
Inflammation
Control Groups
Brain

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Lee, Hee Song ; Song, Junyoung ; Min, Kyunghoon ; Choi, Yong Soo ; Kim, Sun Mi ; Cho, Sung-Rae ; Kim, Min Young. / Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy : A pilot study. In: Brain and Development. 2014 ; Vol. 36, No. 9. pp. 764-769.
@article{be6e0fcdd4804924a93c626ae0e766ba,
title = "Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy: A pilot study",
abstract = "Objective: Cerebral palsy (CP) is a disabling condition characterized by the motor impairment, which is difficult to be ameliorated. In the brain of infants with CP, there are persistent pathomechanisms including accentuated neuroinflammation. Since erythropoietin was demonstrated to have neuroprotective effect via anti-inflammatory and anti-apoptotic properties, we hypothesized that the administration of recombinant human EPO (rhEPO) could help children with CP, especially young infants. Materials and method: We investigated the therapeutic efficacy of rhEPO for infants with CP, who had been undergoing active rehabilitation in hospitalized setting to eliminate treatment bias. Twenty infants with CP were randomly divided into EPO or control group equally. We compared the changes in the Gross Motor Function Measure (GMFM) and the Bayley Scales of Infant Development-II (BSID-II) scores during one month of hospitalization between two groups. Results: The improvements after 1month on the GMFM A and GMFM total scores differed significantly between the groups (p=0.003, p=0.04, respectively). However, the changes after 6months were not different between the two groups. The scores of BSID-II did not show any differences at 1-month and 6-months post-treatment. Conclusion: These results indicated that rhEPO could have therapeutic efficacy for infants with CP during the active rehabilitation and anti-inflammation was suggested to be one of its therapeutic mechanisms.",
author = "Lee, {Hee Song} and Junyoung Song and Kyunghoon Min and Choi, {Yong Soo} and Kim, {Sun Mi} and Sung-Rae Cho and Kim, {Min Young}",
year = "2014",
month = "10",
day = "1",
doi = "10.1016/j.braindev.2013.11.002",
language = "English",
volume = "36",
pages = "764--769",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "9",

}

Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy : A pilot study. / Lee, Hee Song; Song, Junyoung; Min, Kyunghoon; Choi, Yong Soo; Kim, Sun Mi; Cho, Sung-Rae; Kim, Min Young.

In: Brain and Development, Vol. 36, No. 9, 01.10.2014, p. 764-769.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Short-term effects of erythropoietin on neurodevelopment in infants with cerebral palsy

T2 - A pilot study

AU - Lee, Hee Song

AU - Song, Junyoung

AU - Min, Kyunghoon

AU - Choi, Yong Soo

AU - Kim, Sun Mi

AU - Cho, Sung-Rae

AU - Kim, Min Young

PY - 2014/10/1

Y1 - 2014/10/1

N2 - Objective: Cerebral palsy (CP) is a disabling condition characterized by the motor impairment, which is difficult to be ameliorated. In the brain of infants with CP, there are persistent pathomechanisms including accentuated neuroinflammation. Since erythropoietin was demonstrated to have neuroprotective effect via anti-inflammatory and anti-apoptotic properties, we hypothesized that the administration of recombinant human EPO (rhEPO) could help children with CP, especially young infants. Materials and method: We investigated the therapeutic efficacy of rhEPO for infants with CP, who had been undergoing active rehabilitation in hospitalized setting to eliminate treatment bias. Twenty infants with CP were randomly divided into EPO or control group equally. We compared the changes in the Gross Motor Function Measure (GMFM) and the Bayley Scales of Infant Development-II (BSID-II) scores during one month of hospitalization between two groups. Results: The improvements after 1month on the GMFM A and GMFM total scores differed significantly between the groups (p=0.003, p=0.04, respectively). However, the changes after 6months were not different between the two groups. The scores of BSID-II did not show any differences at 1-month and 6-months post-treatment. Conclusion: These results indicated that rhEPO could have therapeutic efficacy for infants with CP during the active rehabilitation and anti-inflammation was suggested to be one of its therapeutic mechanisms.

AB - Objective: Cerebral palsy (CP) is a disabling condition characterized by the motor impairment, which is difficult to be ameliorated. In the brain of infants with CP, there are persistent pathomechanisms including accentuated neuroinflammation. Since erythropoietin was demonstrated to have neuroprotective effect via anti-inflammatory and anti-apoptotic properties, we hypothesized that the administration of recombinant human EPO (rhEPO) could help children with CP, especially young infants. Materials and method: We investigated the therapeutic efficacy of rhEPO for infants with CP, who had been undergoing active rehabilitation in hospitalized setting to eliminate treatment bias. Twenty infants with CP were randomly divided into EPO or control group equally. We compared the changes in the Gross Motor Function Measure (GMFM) and the Bayley Scales of Infant Development-II (BSID-II) scores during one month of hospitalization between two groups. Results: The improvements after 1month on the GMFM A and GMFM total scores differed significantly between the groups (p=0.003, p=0.04, respectively). However, the changes after 6months were not different between the two groups. The scores of BSID-II did not show any differences at 1-month and 6-months post-treatment. Conclusion: These results indicated that rhEPO could have therapeutic efficacy for infants with CP during the active rehabilitation and anti-inflammation was suggested to be one of its therapeutic mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84929939525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929939525&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2013.11.002

DO - 10.1016/j.braindev.2013.11.002

M3 - Article

VL - 36

SP - 764

EP - 769

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 9

ER -